This page shows what was measured, who it was measured in, and what that does not settle.
What Testosterone enanthate does in the body
Replacing testosterone in men whose testes or pituitary gland do not make enough.
Testosterone enanthate is testosterone with a seven-carbon fatty acid attached. That tail makes it oil-soluble and slow to release, so a single injection keeps testosterone in the blood for one to two weeks instead of hours. Once esterases cut the tail off, what circulates is ordinary testosterone: it binds the androgen receptor in muscle to build protein, is converted by aromatase into oestradiol, is converted by 5-alpha-reductase into dihydrotestosterone in skin and prostate, and is read by the hypothalamus and pituitary as a signal to stop making their own. That last effect is why injected testosterone shuts down sperm production, and it is the basis of the male contraceptive trials.
What happened in people
A very high weekly dose increased muscle and strength even without exercise. Combining it with training added more.
✓ Reviewed first-read answer
Where this came from
A person wrote this and a reviewer approved it against this exact record. It carries no effect size.
A reviewer approved this against this record. The reviewed-claim record carrying the exact population and effect size does not exist yet.
No source is stored against this line.
The limit that matters most
Heart-safety evidence studied replacement gel, not high-dose weekly injections.
Where it acts
Androgen receptor in skeletal muscle myonuclei, prostate, bone marrow, liver and central nervous system
Kind of result
Measured performance
Supervision
RNAWiki has not recorded a supervision or regulatory status for this substance.
What the registries record it as
The substance registry classes this as chemical.
FDA substance registry · 7Z6522T8N9 · read 2026-08-29
Where each sentence above came from
No recorded sentence describes the change this makes in a way that stands on its own. The page opens with what it is taken for instead, and the recorded explanation follows below.
Shown as the opening line on this page.
The limit a reviewer approved as the one that matters most here.
The four opening statements run to 143 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Stand-in result
A stand-in result is a number measured because the real result takes too long.
A picture of it, and where the picture fails
It is like judging a journey by the speedometer rather than by arriving.
Where that stops being true. Speed does predict arrival. Many stand-in results do not predict the real one.
What people get wrong. A stand-in result is often reported as the result itself.
A surrogate endpoint substituted for a clinical endpoint, valid only where the substitution has been shown to hold.
Randomisation
Randomisation means chance decides who gets which treatment.
A picture of it, and where the picture fails
It is like a coin toss deciding the groups.
Where that stops being true. A coin toss is fair once. Fairness here comes from doing it for everyone.
What people get wrong. It is thought to make groups identical. It makes them similar on average, including on things nobody measured.
Allocation of participants to arms by a chance process, so that unmeasured factors are balanced in expectation.
Confidence interval
A confidence interval is the range the true answer is likely to sit in.
A picture of it, and where the picture fails
It is like a weather forecast giving a range rather than one number.
Where that stops being true. A forecast range covers tomorrow. This one covers what the study could resolve.
What people get wrong. The middle number is read as the answer. A range crossing zero means no change is still possible.
An interval estimate that would contain the true parameter in a stated proportion of repeated studies.
Formulation
A formulation is the exact made-up form a substance comes in.
A picture of it, and where the picture fails
It is like the difference between a whole bean and instant coffee.
Where that stops being true. Coffee tastes different. A formulation can change how much reaches the blood.
What people get wrong. Two products with the same name are assumed to behave the same. They often do not.
The specific composition and physical form of a product, including salt, excipients and release profile.
What happened in people◇Read from sources, not yet reviewed
What was measured, goal by goal
One row for each goal a registered study measured something for. One column for each kind of thing that could be measured.
Registered studies list 30 outcome measures that RNAWiki could read. A registered study says what someone planned to measure. It does not say what they found. 0 of the matched studies tested this substance, and 0 posted a result.
There is no single score. A strong test result and a weak life result are different facts.
Goals down the side, kinds of measurement across the top. Each cell says what kind of thing was registered, not what was found.
Goal
Life outcome
What a body can do
How a person feels
A test result
A step in the body
Harms
How long
Who was studied
Fertility and sexual health
∅Nothing in the sources checkedNo registered study lists a life outcome for this goal.
∅Nothing in the sources checkedNo registered study lists a performance measure for this goal.
∅Nothing in the sources checkedNo registered study lists a symptom measure for this goal.
△Only a number moved8 registered test measure.
∅Nothing in the sources checkedNo registered study lists a body-step measure for this goal.
—Not recordedHarms were not a registered measure for this goal.
—Not recordedNo finished study window is recorded.
…Waiting for a reviewerWho was studied is listed further down the page.
Strength
∅Nothing in the sources checkedNo registered study lists a life outcome for this goal.
…Waiting for a reviewer2 registered performance measure of this kind.
∅Nothing in the sources checkedNo registered study lists a symptom measure for this goal.
∅Nothing in the sources checkedNo registered study lists a test result for this goal.
∅Nothing in the sources checkedNo registered study lists a body-step measure for this goal.
—Not recordedHarms were not a registered measure for this goal.
—Not recordedNo finished study window is recorded.
…Waiting for a reviewerWho was studied is listed further down the page.
Muscle
∅Nothing in the sources checkedNo registered study lists a life outcome for this goal.
∅Nothing in the sources checkedNo registered study lists a performance measure for this goal.
∅Nothing in the sources checkedNo registered study lists a symptom measure for this goal.
△Only a number moved2 registered test measure.
∅Nothing in the sources checkedNo registered study lists a body-step measure for this goal.
—Not recordedHarms were not a registered measure for this goal.
—Not recordedNo finished study window is recorded.
…Waiting for a reviewerWho was studied is listed further down the page.
Body weight
∅Nothing in the sources checkedNo registered study lists a life outcome for this goal.
∅Nothing in the sources checkedNo registered study lists a performance measure for this goal.
∅Nothing in the sources checkedNo registered study lists a symptom measure for this goal.
△Only a number moved2 registered test measure.
∅Nothing in the sources checkedNo registered study lists a body-step measure for this goal.
—Not recordedHarms were not a registered measure for this goal.
—Not recordedNo finished study window is recorded.
…Waiting for a reviewerWho was studied is listed further down the page.
Which registered measures put each goal on this table
Fertility and sexual health
serum total testosterone measured on treatment day 2; serum total testosterone measured on treatment day 3; serum total testosterone measured on treatment day 4; serum total testosterone measured on treatment day 5; serum total testosterone measured on treatment day 6; serum total testosterone measured on treatment day 7; serum total testosterone measured on treatment day 8; serum testosterone cavg
Strength
1 repetition maximum strength testing; muscle strength
Muscle
changes in lean mass; pelvic floor muscle volume
Body weight
total body fat; body composition at the end of each study phase
Sorted by fixed word lists, version v1. A name the rules do not recognise stays unsorted rather than moving to the nearest column.
What each mark on this table means
∅ Nothing in the sources checked
No registered study lists a life outcome for this goal.
△ Only a number moved
8 registered test measure.
— Not recorded
Harms were not a registered measure for this goal.
… Waiting for a reviewer
Who was studied is listed further down the page.
What happened in people◇Read from sources, not yet reviewed
What happened in people
Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.
Fat-free mass by underwater weighing, muscle cross-sectional area by MRI, bench press and squat strength
✓ The study showed what it set out to show
Who was studied
Bhasin 1996 randomised four-arm trial in normal men
Testosterone without exercise vs placebo without exercise: triceps area P < 0.05, quadriceps area P < 0.05, bench press P < 0.05, squat P < 0.05; testosterone plus exercise fat-free mass +6.1 +/- 0.6 kg
Repeated elsewhere
Replicated
What this does not prove. Meeting one endpoint in one population does not carry to other goals or other people.
The limits of this study, and where it came from
Main limit. Neither mood nor behaviour was altered in any group, contradicting the contemporary expectation of steroid-induced aggression at this dose over this duration.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Intramuscular oil injection, or weekly subcutaneous autoinjector at 50, 75 or 100 mg
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
WHO Task Force on Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men.… · a recorded source, not a stored snapshot
WHO Task Force on Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet 1990;336:955… · a recorded source, not a stored snapshot
Pregnancy incidence in couples relying solely on weekly 200 mg intramuscular testosterone enanthate
✓ The study showed what it set out to show
Who was studied
WHO Task Force male contraceptive efficacy study
How many people
399
Study design
Prospective non-comparative efficacy, 15 centres in 9 countries
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Azoospermic men 0.0 pregnancies per 100 person-years (95% CI 0.0-1.6) over 230.4 person-years; oligozoospermic men 8.1 per 100 person-years (95% CI 2.2-20.7) over 49.5 person-years
Repeated elsewhere
Replicated
What this does not prove. Meeting one endpoint in one population does not carry to other goals or other people.
The limits of this study, and where it came from
Main limit. 35 of 399 men discontinued for medical reasons (9.4%, 95% CI 6.7-13.2) with no serious treatment-related side effects reported; suppression failed in 8 men and 4 escaped suppression.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Intramuscular oil injection, or weekly subcutaneous autoinjector at 50, 75 or 100 mg
Interval reported. 95% CI 0
Written into the record, not signed off as a reviewed claim.
WHO Task Force on Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men.… · a recorded source, not a stored snapshot
WHO Task Force on Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet 1990;336:955… · a recorded source, not a stored snapshot
Hazard ratio 0.96 (95% CI 0.78-1.17), P < 0.001 for non-inferiority; 182 of 2,601 events on testosterone vs 190 of 2,603 on placebo
Repeated elsewhere
Unreplicated
What this does not prove. Meeting one endpoint in one population does not carry to other goals or other people.
The limits of this study, and where it came from
Main limit. Higher incidence of atrial fibrillation, acute kidney injury and pulmonary embolism in the testosterone group. The intervention was 1.62% transdermal gel titrated to 350-750 ng/dL, not injectable enanthate.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Intramuscular oil injection, or weekly subcutaneous autoinjector at 50, 75 or 100 mg
Interval reported. 95% CI 0
Written into the record, not signed off as a reviewed claim.
WHO Task Force on Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men.… · a recorded source, not a stored snapshot
WHO Task Force on Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet 1990;336:955… · a recorded source, not a stored snapshot
Reproductive hormones, semen variables, testicular volume, body composition and cardiac systolic function by user status
✓ The study showed what it set out to show
Who was studied
Shankara-Narayana 2020 recovery cohort
How many people
93
Study design
Cross-sectional observational, current users, past users and non-users
Compared against
Not recorded for this study
Kind of result
What a body can do day to day
What was found
Past users indistinguishable from non-users except testicular volume and SHBG; mean recovery 7.3 months for AMH, 10.7 months for LH, 14.1 months for sperm output
Repeated elsewhere
Unreplicated
What this does not prove. Meeting one endpoint in one population does not carry to other goals or other people.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Intramuscular oil injection, or weekly subcutaneous autoinjector at 50, 75 or 100 mg
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
WHO Task Force on Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men.… · a recorded source, not a stored snapshot
WHO Task Force on Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet 1990;336:955… · a recorded source, not a stored snapshot
RNAWiki holds 4 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.
What happened in people◇Read from sources, not yet reviewed
How close this is to real life
The top step is something a person would feel or care about. The bottom is a guess from software. Filled steps are where evidence exists for this substance.
■Living longer, or avoiding a major eventEvidence recorded. Death, a heart attack, a stroke, a hospital stay.1 registered measure of this kind. No reviewed result.
■What a body can do day to dayEvidence recorded. Walking, dressing, breathing, recovering.4 registered measures of this kind.
■Measured performanceEvidence recorded. How much was lifted, how far was run, how fast.4 registered measures of this kind.
□Symptoms and quality of lifeNo evidence recorded. Pain, tiredness, mood, sleep, as the person rated it.No registered study measures this.
■A number that stands in for healthEvidence recorded. Cholesterol, blood sugar, bone density. A stand-in, not the thing itself.15 registered measures of this kind.
■A step measured inside a personEvidence recorded. Something measured in human tissue or human cells.A human record sits on the stored organism ladder.
□AnimalsNo evidence recorded. Mice, rats, dogs. Useful for ideas, not proof about people.No animal record is stored.
□Cells in a dishNo evidence recorded. Cells or chemistry on a bench, far from a whole body.No cell or bench record is stored.
□A guess from softwareNo evidence recorded. Nobody measured it. RNAWiki never publishes one as a finding.RNAWiki stores no prediction for this record. Software can suggest a link. RNAWiki does not publish one as a finding.
Higher on these steps means closer to something a person would feel. It does not mean better done.
What it changes in the body◇Read from sources, not yet reviewed
The path through the body
From what a person takes to what changes. A solid line is a step measured in people. A dashed line is a step nobody has measured that way.
Start
Testosterone enanthate
What a person takes: Intramuscular oil injection, or weekly subcutaneous autoinjector at 50, 75 or 100 mg.
The measurement behind this step
A sterile solution of the ester in sesame oil. The approved subcutaneous product is a single-dose pressure-assisted autoinjector; the older intramuscular presentation is a multi-dose vial. Release from the oil depot is the rate-limiting step, giving a roughly weekly dosing interval.
Getting in
An oil depot that releases for a week or more
The drug is injected into muscle or under the skin as an oil, and the fatty tail on the molecule makes it leave that depot slowly.
╌╌Described, with no measurement named. No measurement is named for this step, so it is drawn as an unconfirmed link.
The measurement behind this step
Testosterone enanthate in sesame oil forms an intramuscular or subcutaneous depot. Partition out of the oil is rate-limiting, giving a terminal half-life of days rather than the roughly 10-90 minutes of free testosterone. The approved subcutaneous autoinjector delivers 50, 75 or 100 mg weekly; the trials that defined supraphysiological effects used 600 mg weekly intramuscularly.
WHO Task Force on Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men.… · a recorded source, not a stored snapshot
WHO Task Force on Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet 1990;336:955… · a recorded source, not a stored snapshot
Reaching the cell
Esterases cut the tail off
Enzymes in blood and tissue snip off the fatty chain, leaving plain testosterone.
──Measured in people. Written by a person from the study named beside the step. Not signed off as a reviewed claim.
The measurement behind this step
Non-specific plasma and tissue esterases hydrolyse the 17beta-heptanoate to free testosterone and heptanoic acid. The ester is a pharmacokinetic device only; every downstream effect belongs to testosterone itself, which is why the ester chosen changes the shape of the curve and not the pharmacology.
WHO Task Force on Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men.… · a recorded source, not a stored snapshot
WHO Task Force on Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet 1990;336:955… · a recorded source, not a stored snapshot
What it acts on
Three signals, not one
Testosterone acts directly, and is also converted into a stronger androgen in skin and prostate and into oestrogen in fat. All three matter.
╌╌Described, with no measurement named. No measurement is named for this step, so it is drawn as an unconfirmed link.
The measurement behind this step
Free testosterone binds the androgen receptor directly; 5-alpha-reductase converts it to dihydrotestosterone, a higher-affinity AR ligand concentrated in skin, scalp and prostate; aromatase (CYP19A1) converts it to oestradiol, which acts at oestrogen receptors and is required for normal male bone and lipid physiology. The off-label use of aromatase inhibitors alongside injected testosterone is an attempt to interrupt the third arm.
WHO Task Force on Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men.… · a recorded source, not a stored snapshot
WHO Task Force on Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet 1990;336:955… · a recorded source, not a stored snapshot
The change it makes
Muscle protein synthesis up, endogenous production off
Muscle cells build more protein. At the same time the brain sees plenty of testosterone and stops telling the testes to make any.
╌╌Described, with no measurement named. No measurement is named for this step, so it is drawn as an unconfirmed link.
The measurement behind this step
Ligand-bound AR drives myonuclear transcription with increased satellite cell number and muscle protein synthesis; the same signal at the hypothalamus and pituitary suppresses GnRH, LH and FSH by negative feedback, collapsing intratesticular testosterone and spermatogenesis. Testosterone also suppresses hepcidin, which raises iron availability for erythropoiesis and explains the polycythaemia seen at replacement dose.
WHO Task Force on Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men.… · a recorded source, not a stored snapshot
WHO Task Force on Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet 1990;336:955… · a recorded source, not a stored snapshot
What that does for a person
Measured gains, measured costs, both reversible
Muscle and strength go up in a dose-dependent way. Sperm production, HDL cholesterol and heart contractility go the other way, and they come back over six to eighteen months after stopping.
╌╌Described, with no measurement named. No measurement is named for this step, so it is drawn as an unconfirmed link.
The measurement behind this step
Fat-free mass and strength rise with dose in randomised trials. Current users show suppressed reproductive hormones, impaired cardiac systolic function and adverse lipoproteins; past users are indistinguishable from never-users except for testicular volume and SHBG, with hormone recovery in 7-11 months and sperm output in about 14 months.
WHO Task Force on Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men.… · a recorded source, not a stored snapshot
WHO Task Force on Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet 1990;336:955… · a recorded source, not a stored snapshot
No suggested links are held for this record, so nothing is hidden from this path.
What we know
The record describes 5 steps from taking it to an effect in a person.
How we know it
Each step names the study behind it in the technical detail beside it.
What this does not prove
A change inside the body is a reason to look. It is not a result in a person.
Why it matters
A reader can see exactly where the chain stops being measured in people.
What we still do not know
No reviewed claim binds any of these steps to a named population.
What it would be like to take◇Read from sources, not yet reviewed
Felt, measured, or meaningful
Three different things that get called the same word. Registered studies measured all three, and mixing them is how a blood test becomes a health claim.
Felt
Things a person could notice without a test.
No registered study measured anything of this kind.
Measured
Things only a test, a scale or a device shows.
1 repetition maximum strength testing
serum total testosterone measured on treatment day 2
serum total testosterone measured on treatment day 3
serum total testosterone measured on treatment day 4
serum total testosterone measured on treatment day 5
serum total testosterone measured on treatment day 6
serum total testosterone measured on treatment day 7
serum total testosterone measured on treatment day 8
serum estradiol measured on treatment day 1
serum estradiol measured on treatment day 8
and 7 more.
Meaningful
Things that change how a life goes, not only a number.
walking speed
clinical or radiographic progression free survival
6 min walk test
A registered study says what someone planned to measure. It does not say what they found. A number moving is not the same as a life going better. The two are shown apart here.
Felt, but not shown to help. A person notices a change. No study showed it leads anywhere good.
Measured, but not felt. A number moves. The person notices nothing. Both can be true.
Measured, but not shown to matter. A number moves in the good direction. Nobody showed that lives went better.
Matters, but takes years. The result that counts may take longer than anyone would keep watching.
Names that fit none of the three (10)
fat free mass measured by dexa scanning
clinical adverse events
laboratory adverse events
bone density
changes in muscle cross sectional area
fat free mass as measured by bioelectric impediance analysis
physical performance
who experienced an ae
psa response rate
who discontinue pes due to traes
These are harms, study-process measures, or names the rules did not recognise. They are shown rather than dropped.
What is missing or unclear◇Read from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
People similar to this profile were included.
Men with diagnosed hypogonadism on prescription. Also, at four to twenty times the replacement dose, men using it for muscle mass, in which context it is the most commonly used and most commonly counterfeited anabolic steroid in the world.
Who is missing from the studies
Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What the label states about particular groups
On pediatric, the label states: “Safety and effectiveness of XYOSTED in pediatric patients less than 18 years old have not been established.”
US prescribing information · 8a3d204c-be26-49e0-8599-0ac12a272e81 · read 2026-08-30
On older people, the label states: “There have not been sufficient numbers of geriatric patients in controlled clinical studies with XYOSTED to determine whether efficacy or safety in those over 65 years of age differs from younger subjects.”
US prescribing information · 8a3d204c-be26-49e0-8599-0ac12a272e81 · read 2026-08-30
On people who are pregnant, the label states: “Risk Summary XYOSTED is contraindicated in pregnant women.”
US prescribing information · 8a3d204c-be26-49e0-8599-0ac12a272e81 · read 2026-08-30
On people who are breastfeeding, the label states: “Risk Summary XYOSTED is not indicated for use in females.”
US prescribing information · 8a3d204c-be26-49e0-8599-0ac12a272e81 · read 2026-08-30
Where the result stopped carrying
Before 1996 the medical literature described the efficacy of androgens for strength as unsubstantiated; the randomised trial that settled it was run because the claim had never been tested properly
Testosterone enanthate monotherapy failed as a marketable male contraceptive not on efficacy but on regimen: weekly injections and incomplete suppression in a minority of men
This is a scope explorer, not a diagnosis engine.
It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to take◇Read from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
It was studied for a different goal
The studies measured something else entirely.
On this record: Some registered studies measured things that match no goal on this page.
It was studied in different people
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
A different form was studied
The studied form is not the form on the shelf.
On this record: This record is linked to 1 related forms. Evidence does not carry across all of them.
The evidence may simply be wrong
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (9)
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to take◇Read from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Given by a clinician
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Intramuscular oil injection, or weekly subcutaneous autoinjector at 50, 75 or 100 mg
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form and route recorded on this substance.
No source is stored against this line.
Who oversees it
RNAWiki has not recorded a supervision or regulatory status for this substance.
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
No register row and no identity class settled the question.
No source is stored against this line.
What is in the pack
A sterile solution of the ester in sesame oil. The approved subcutaneous product is a single-dose pressure-assisted autoinjector; the older intramuscular presentation is a multi-dose vial. Release from the oil depot is the rate-limiting step, giving a roughly weekly dosing interval.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on how this is sold and what that means for what is in the pack.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
# Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to take◇Read from sources, not yet reviewed
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
·Worth asking a clinician aboutWritten into the record from the studies named on this page
Labelled warnings at replacement dose: polycythaemia requiring haematocrit monitoring, venous thromboembolism, worsening benign prostatic hyperplasia and potential prostate cancer risk, blood pressure increases with the product not recommended in uncontrolled hypertension, azoospermia, and oedema. At supraphysiological doses the measured additional findings are impaired cardiac systolic function, adverse lipoprotein changes and suppressed reproductive hormones in current users, all of which recovered in past users over 6 to 18 months apart from testicular volume.
Nobody counted how many people took this and were fine, so this cannot be turned into a rate.
WHO Task Force on Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men.… · a recorded source, not a stored snapshot
WHO Task Force on Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet 1990;336:955… · a recorded source, not a stored snapshot
Reports sent to a regulator
These are reports people sent to a regulator. They do not show the medicine caused the reaction.
Nobody counted how many people took the medicine and reported nothing.
The same event can be reported more than once, and many reports are incomplete.
News coverage, lawsuits and new warnings change how often people report.
A count is not a rate and not a risk.
Testosterone enanthate appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 1361 reaction mentions were counted. One report can name several reactions.
open-targets-adr · recorded 2026-06-24 · a recorded source, not a stored snapshot
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclear◇Read from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Intramuscular oil injection, or weekly subcutaneous autoinjector at 50, 75 or 100 mg
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form used in the studies cited on this page.
No source is stored against this line.
What is sold
The approved subcutaneous product is a single-dose pressure-assisted autoinjector; the older intramuscular presentation is a multi-dose vial. Release from the oil depot is the rate-limiting step, giving a roughly weekly dosing interval.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on which forms are sold and how they compare.
No source is stored against this line.
What is recorded as being sold
19 products list this as an active ingredient in the United States drug directory. 19 of them contain it and nothing else.
FDA National Drug Code directory · 54436-200 · read 2026-08-29
They are sold as injection, injection, solution and powder, taken intramuscular and subcutaneous.
FDA National Drug Code directory · 54436-200 · read 2026-08-29
The regulator's established pharmacologic class for it is androgen receptor agonists [moa], androgen [epc] and androstanes [cs].
FDA National Drug Code directory · 54436-200 · read 2026-08-29
3 published labels name it as an active ingredient. 3 of them describe this substance alone, which is where its own label text on this page comes from.
US prescribing information · 8a3d204c-be26-49e0-8599-0ac12a272e81 · read 2026-08-29
Those labels are classed as human prescription drug.
US prescribing information · 8a3d204c-be26-49e0-8599-0ac12a272e81 · read 2026-08-29
XYOSTED is subcutaneous at 3 DOSAGE FORMS AND STRENGTHS XYOSTED injection is available as 0.5 mL of a sterile, preservative-free and nonpyrogenic, clear, colorless to yellow solution containing testosterone enanthate., recorded as fda label in effect 2025-07-01 in the United States.
US prescribing information · 8a3d204c-be26-49e0-8599-0ac12a272e81 · read 2026-08-30
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
Evidence on this page does not automatically apply to this one.
What it would be like to take◇Read from sources, not yet reviewed
What you could measure
This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.
RNAWiki could not confidently classify this substance, so no self-experiment plan is offered.
Questions worth asking
Which of the trials of Testosterone enanthate studied people like me?
What was measured, and for how long?
Was the result a laboratory value or a health outcome?
What would we watch for, and when would we stop?
Tracking can show whether something changed for you. It cannot show what caused it.
RNAWiki records evidence. It does not say whether this substance is right for you.
What is missing or unclear◇Read from sources, not yet reviewed
Claims that go past the evidence
Things said about this substance that sound reasonable, and the exact step that is missing between the evidence and the claim.
✗Goes past the evidence
That the TRAVERSE cardiovascular result applies to injectable testosterone at supraphysiological dose — different drug form, different dose, different population
Why it sounds right. It follows from something real on this page: a body step, an animal result or a related finding.
The missing step. Nobody measured this in people for this use, or the study that did measure it did not show it.
What would change this
A study in people, for this exact use, measuring this exact thing, that a reviewer signs off.
RNAWiki has not yet published a reviewed conclusion for this use.
✗Goes past the evidence
That because 600 mg weekly did not alter mood in a 10-week trial, longer or higher-dose use has no psychiatric effect; the trial measured 10 weeks
Why it sounds right. It follows from something real on this page: a body step, an animal result or a related finding.
The missing step. Nobody measured this in people for this use, or the study that did measure it did not show it.
What would change this
A study in people, for this exact use, measuring this exact thing, that a reviewer signs off.
RNAWiki has not yet published a reviewed conclusion for this use.
✗Goes past the evidence
That an ampoule labelled testosterone enanthate contains testosterone enanthate at the stated concentration, which in seizure analyses is the exception
Why it sounds right. It follows from something real on this page: a body step, an animal result or a related finding.
The missing step. Nobody measured this in people for this use, or the study that did measure it did not show it.
What would change this
A study in people, for this exact use, measuring this exact thing, that a reviewer signs off.
RNAWiki has not yet published a reviewed conclusion for this use.
✗Goes past the evidence
That the label indication covers age-related low testosterone, which the label explicitly states has not been established
Why it sounds right. It follows from something real on this page: a body step, an animal result or a related finding.
The missing step. Nobody measured this in people for this use, or the study that did measure it did not show it.
What would change this
A study in people, for this exact use, measuring this exact thing, that a reviewer signs off.
RNAWiki has not yet published a reviewed conclusion for this use.
What is missing or unclear◇Read from sources, not yet reviewed
What nobody knows yet
Open questions, each with why it is open and what would close it.
How fast does the body clear it?
The sources RNAWiki checked hold nothing for this field.
Why it matters. Without this, nothing on this page can say how long anything lasts.
What would answer it
A stored source that records it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing populations
Which groups were under-represented in the studies has not been recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing long-term data
No completed tested study window is recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
No reviewed conclusion
RNAWiki has not yet published a reviewed conclusion for this use.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing interaction studies
No interaction was found in the registers checked. Not finding one is not the same as showing there is none.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Formulation uncertainty
Several salts, forms or products of Testosterone enanthate are recorded. Results from one form may not transfer to another.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Mechanism not reviewed
No reviewed mechanism story exists for this substance.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
What happened in people◇Read from sources, not yet reviewed
Check any of this yourself
Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.
Every line above can be traced to the study named beside it. Follow the link and read it.
The trial that settled whether anabolic steroids work: 6.1 kg of fat-free mass
In plain words
Forty-three men were randomised to testosterone or placebo, with or without weight training, for ten weeks. Testosterone without any exercise beat placebo on muscle size and strength. Testosterone plus training beat everything.
What was measured
Fat-free mass by underwater weighing, triceps and quadriceps cross-sectional area by MRI, and bench press and squat strength at 10 weeks
Effect estimate
No reviewed effect estimate exists for this record.
Limits
See the technical detail.
From the source
Bhasin et al. randomised 43 normal men to four arms: placebo without exercise, testosterone without exercise, placebo plus exercise, and testosterone plus exercise. All received 600 mg of testosterone enanthate or placebo by weekly injection for 10 weeks. Fat-free mass was measured by underwater weighing and muscle size by magnetic resonance imaging. Among the non-exercising men, testosterone produced greater increases than placebo in triceps area (424 +/- 104 vs -81 +/- 109 square millimetres, P < 0.05), quadriceps area (607 +/- 123 vs -131 +/- 111 square millimetres, P < 0.05), bench press strength (9 +/- 4 vs -1 +/- 1 kg, P < 0.05) and squat (16 +/- 4 vs 3 +/- 1 kg, P < 0.05). The testosterone-plus-exercise arm gained 6.1 +/- 0.6 kg of fat-free mass, with bench press up 22 +/- 2 kg and squat up 38 +/- 4 kg. Neither mood nor behaviour was altered in any group. Before this trial the efficacy of androgens for strength was described in the medical literature as unsubstantiated.
Written into the record, not signed off as a reviewed claim
Zero pregnancies in 230 person-years of testosterone-induced azoospermia
In plain words
A WHO study gave 399 fertile men weekly testosterone injections as a contraceptive. Among the men whose sperm counts fell to zero, no partner became pregnant across 230 person-years of exposure.
What was measured
Pregnancy rate per 100 person-years in couples relying solely on weekly 200 mg testosterone enanthate
Effect estimate
No reviewed effect estimate exists for this record.
Limits
See the technical detail.
From the source
The WHO Task Force on Methods for the Regulation of Male Fertility ran a prospective efficacy study at 15 centres in nine countries in 399 normal fertile men requesting a male contraceptive method, using weekly intramuscular 200 mg testosterone enanthate. Four pregnancies occurred during 49.5 person-years among men suppressed only to oligozoospermia (0.1-3 million per mL), a rate of 8.1 per 100 person-years (95% CI 2.2-20.7). None occurred during 230.4 person-years among azoospermic men, a rate of 0.0 (95% CI 0.0-1.6). Suppression failed in eight men and four escaped from suppression. Thirty-five men discontinued for medical reasons (9.4%) with no serious treatment-related side effects. Sperm output recovered after stopping and fertility was demonstrated in 33 couples. This is the cleanest measurement anywhere of what exogenous testosterone does to the hypothalamic-pituitary-gonadal axis, and it is the reason infertility is a predictable consequence rather than a rare complication.
Source
WHO Task Force on Methods for the Regulation of Male Fertility, Fertil Steril 1996;65:821-829 (PMID 8654646); earlier azoospermia-only report, Lancet 1990;336:955-959 (PMID 1977002)
Role in the trial
Not matched to a registered study
Identity check
no open identity hold
Audit mark
verified
Review state
Written into the record, not signed off as a reviewed claim
The cardiovascular safety trial used a gel at replacement dose
In plain words
TRAVERSE is quoted as showing testosterone is safe for the heart. It studied a daily gel titrated to a normal testosterone level in men with low testosterone, not weekly injections at four to twenty times that dose.
What was measured
That the TRAVERSE non-inferiority result extends to supraphysiological injectable testosterone, when the trial titrated a gel to the mid-normal range in deficient men
Effect estimate
No reviewed effect estimate exists for this record.
Limits
See the technical detail.
From the source
TRAVERSE (NCT03518034) randomised 5,246 men aged 45-80 with pre-existing or high cardiovascular risk and two fasting testosterone levels below 300 ng/dL to daily transdermal 1.62% testosterone gel, titrated to keep testosterone between 350 and 750 ng/dL, or placebo gel. Mean treatment duration was 21.7 months and mean follow-up 33.0 months. A primary MACE event occurred in 182 (7.0%) on testosterone and 190 (7.3%) on placebo, hazard ratio 0.96 (95% CI 0.78-1.17), P < 0.001 for non-inferiority. The trial also found a higher incidence of atrial fibrillation, acute kidney injury and pulmonary embolism in the testosterone group. Every element of that design — the route, the dose, the titration target, the population — differs from supraphysiological injectable use. The trial establishes non-inferiority for replacement; it says nothing measured about 600 mg weekly.
Written into the record, not signed off as a reviewed claim
Suppression is reversible, and it takes 6 to 18 months
In plain words
Men who had stopped using androgens were compared with current users and with non-users. Reproductive and heart function came back, but recovery took roughly half a year to a year and a half, and testicle volume did not fully return.
What was measured
Time to normalisation of AMH, LH, FSH, inhibin B, sperm output and cardiac systolic function after cessation, against never-users
Effect estimate
No reviewed effect estimate exists for this record.
Limits
See the technical detail.
From the source
Shankara-Narayana et al. recruited 41 current androgen users, 31 past users (at least 3 months since last use, median 300 days) and 21 healthy eugonadal non-users, each providing history, examination, serum and semen samples, testicular ultrasound, body composition and cardiac function assessment. Current users had suppressed reproductive function and impaired cardiac systolic function and lipoprotein parameters relative to both other groups. Past users did not differ from non-users except for residual reduced testicular volume and sex hormone binding globulin. Mean time to recovery was 7.3 months for anti-Mullerian hormone and 10.7 months for luteinising hormone, 14.1 months for sperm output, and longer for FSH and inhibin B. Duration of use was the only variable associated with slower recovery of sperm output. The finding runs in both directions: the harms are real and measured in current users, and they are also reversible on a timescale of 6 to 18 months.
Written into the record, not signed off as a reviewed claim
What the label itself warns about, at replacement dose
In plain words
The approved product information lists raised red cell count, clots, worsening prostate enlargement, raised blood pressure and loss of sperm production as expected effects at ordinary replacement doses.
What was measured
Labelled warnings and precautions at approved replacement doses of testosterone enanthate
Effect estimate
No reviewed effect estimate exists for this record.
Limits
See the technical detail.
From the source
The Xyosted (testosterone enanthate autoinjector, NDA 209863, approved 28 September 2018) prescribing information carries warnings for polycythaemia with haematocrit monitoring approximately every three months; venous thromboembolism including deep vein thrombosis and pulmonary embolism; worsening of benign prostatic hyperplasia and potential prostate cancer risk; blood pressure increases, with the product not recommended in men with uncontrolled hypertension; abuse of testosterone, described in the label as typically occurring at doses higher than the approved indication and in combination with other anabolic androgenic steroids; azoospermia from exogenous androgen administration; and oedema. The label also states that safety and efficacy in age-related hypogonadism have not been established. These are the effects at the approved dose, in monitored patients, from the manufacturer own document.
Written into the record, not signed off as a reviewed claim
Testosterone esters are the most counterfeited drug in the seizure literature
In plain words
Analyses of seized products repeatedly find that ampoules labelled as testosterone contain a different ester, a different steroid, or a different amount.
What was measured
Proportion of seized anabolic steroid products matching their label: under 20% of 1,190 Swiss items, 4 of 54 French AAS products
Effect estimate
No reviewed effect estimate exists for this record.
Limits
See the technical detail.
From the source
Weber et al. analysed 1,190 products seized at the Swiss border; labels claimed anabolic agents for 889 (75%), and fewer than 20% of all products contained the claimed substance in the claimed amount. Fabresse et al. analysed 110 products seized from the French bodybuilding black market: of the 54 containing anabolic-androgenic steroids, only 4 (7.4%) matched their label both qualitatively and quantitatively, 33% were substandard in dose and 32% were counterfeit in composition, giving 43 of 54 (80%) non-original. Because the ester determines release kinetics, an ampoule labelled enanthate that contains propionate produces an entirely different blood-level curve from the same injection schedule. This is a pharmacokinetic problem, not just a consumer-protection one.
This order is fixed in code and does not count clicks or time on the page.
What is not here
4 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
How long anything takes — found nothing in the sources checked.
What it may clash with — found nothing in the sources checked.
Other ways to the same goal — found nothing in the sources checked.
What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
The older medicine-wide conclusion held in this record
Written for a clinical reader, and about the medicine as a whole rather than about one indication, population and set of trials. RNAWiki does not treat it as a programme conclusion and no reviewer has signed it off in that form. It is here word for word because it is what the record holds.
The only anabolic steroid with a real dose-response literature in humans: 600 mg per week for ten weeks added 6.1 kg of fat-free mass with training in a randomised trial, 200 mg per week produced azoospermia with zero pregnancies across 230 person-years, and the cardiovascular outcome trial everyone cites used a gel at replacement dose, not this ester at these doses.
Recorded evidence blocks (12)
Q1
What did Testosterone enanthate's largest trial (222 people) and its longest (9.4 years) measure?
222 people in Testosterone enanthate's largest registered study, 9.4 years in its longest registered window, measuring The Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] of Testosterone Enanthate Formulations at 6 Weeks. ClinicalTrials.gov · 2026-09-01
17 phase2, 10 phase3, 8 phase1, 5 phase4, 1 early phase1, 1 na; NCT03522064; 2027-12-30. Last human test completed 2024, NCT03516812.
Interpretation These counts include studies where Testosterone enanthate was a comparison treatment, a background treatment or an exposure in an observational study, and the longest window may be a planned end date. Trial roles have not yet been classified for this record.
Show the evidence
phase2
17
phase3
10
phase1
8
phase4
5
early phase1
1
na
1
1 more recorded row
Last recorded human testNCT03516812
2024-04-12
recorded 2026-09-01 · last checked 2026-09-04
Q2
Testosterone enanthate was tested only in human — what did it show?
The Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] of Testosterone Enanthate Formulations at 6 Weeks — the recorded outcome words.
Show the evidence
humanNCT01887418
biomarker; The Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] of Testosterone Enanthate Formulations at 6 Weeks; 38
recorded 2026-09-01 · last checked 2026-09-04
Q3
5 of Testosterone enanthate's trials stopped: accrual/recruitment, funding/business?
Could one person measure Testosterone enanthate's effect on walking speed?
Walking speed: measured in Testosterone enanthate's trials.
Interpretation walking speed is the recorded endpoint.
Show the evidence
biomarkers
walking speed; 2026-09-01
1 repetition maximum strength testing; 2026-09-01
fat free mass measured by dexa scanning; 2026-09-01
serum total testosterone measured on treatment day 2; 2026-09-01
serum total testosterone measured on treatment day 3; 2026-09-01
serum total testosterone measured on treatment day 4; 2026-09-01
14 more recorded rows
biomarkers
serum total testosterone measured on treatment day 5; 2026-09-01
biomarkers
serum total testosterone measured on treatment day 6; 2026-09-01
biomarkers
serum total testosterone measured on treatment day 7; 2026-09-01
biomarkers
serum total testosterone measured on treatment day 8; 2026-09-01
biomarkers
serum estradiol measured on treatment day 1; 2026-09-01
biomarkers
serum estradiol measured on treatment day 8; 2026-09-01
biomarkers
clinical adverse events; 2026-09-01
biomarkers
laboratory adverse events; 2026-09-01
biomarkers
muscle strength; 2026-09-01
biomarkers
bone density; 2026-09-01
biomarkers
changes in lean mass; 2026-09-01
biomarkers
hip bone mineral density; 2026-09-01
biomarkers
changes in muscle cross sectional area; 2026-09-01
biomarkers
total body fat; 2026-09-01
human trials at or under30
13
Not recorded for this substance
a recorded half-life
smallest human trial
0; NCT01417364; PHASE4; the smallest recorded human enrolment at or below 30; the registry states no direction of its result; WITHDRAWN
Q6
Which of 1 repetition maximum strength testing, 6 min walk test and body composition at the end of each study phase did Testosterone enanthate's trials measure?
1 repetition maximum strength testing, 6 min walk test and body composition at the end of each study phase lead 30 outcome terms across Testosterone enanthate's trials. ClinicalTrials.gov · 2026-09-01
serum total testosterone measured on treatment day 2, serum total testosterone measured on treatment day 3, serum total testosterone measured on treatment day 4, serum total testosterone measured on treatment day 5, serum total testosterone measured on treatment day 6 and serum total testosterone measured on treatment day 7 follow.
Show the evidence
walking speed
1
1 repetition maximum strength testing
1
fat free mass measured by dexa scanning
1
serum total testosterone measured on treatment day 2
1
serum total testosterone measured on treatment day 3
1
serum total testosterone measured on treatment day 4
1
14 more recorded rows
serum total testosterone measured on treatment day 5
1
serum total testosterone measured on treatment day 6
1
serum total testosterone measured on treatment day 7
1
serum total testosterone measured on treatment day 8
1
serum estradiol measured on treatment day 1
1
serum estradiol measured on treatment day 8
1
clinical adverse events
1
laboratory adverse events
1
muscle strength
1
bone density
1
changes in lean mass
1
hip bone mineral density
1
changes in muscle cross sectional area
1
total body fat
1
recorded 2026-09-01 · last checked 2026-09-04
Q7
Which of Testosterone enanthate's 6 ongoing trials reports first?
"Bipolar Androgen Therapy + Carboplatin in mCRPC"; n 30; "PSA Response Rate"; 2027-12-30
NCT04363164
"Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression"; n 150; "Clinical or Radiographic Progression free survival"; 2028-07
NCT04460872
"Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury"; n 21; "change in thigh muscle cross-sectional area"; 2026-06-30
NCT06594926
"Working Out M0 Bipolar Androgen Therapy"; n 69; "Metastases free survival"; 2028-12-31
NCT06689085
"52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism"; n 100; "Increase in testosterone, as evaluated using PK parameters"; 2030-03
NCT07568574
"Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes"; n 60; "The incidence and severity of Treatment-related adverse events (TRAEs), including adverse events (AEs) and serious adverse events (SAEs), as assessed by the study physicians from baseline to 5.5 years after enrollment."; 2033-03-01
recorded 2026-09-01 · last checked 2026-09-04
Q8
Which running trial of Testosterone enanthate could settle lifespan?
NCT04363164 measures Clinical or Radiographic Progression free survival, reading out 2028-07.
2 open trials; n 150; "Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression"
Show the evidence
Trial
NCT04363164
"Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression"; n 150; "Clinical or Radiographic Progression free survival"; 2028-07
NCT06594926
"Working Out M0 Bipolar Androgen Therapy"; n 69; "Metastases free survival"; 2028-12-31
Q9
Which 10 trials of Testosterone enanthate posted no result?
Posted no result
10 of 10 completed trials
Registrations
NCT00001079, NCT00161304, NCT00260143, NCT00399165, NCT01017458 and NCT00493987, and 4 more
Completion dates
oldest 2002-12; newest 2020-11-08
Show the evidence
Trial
NCT00001079
2002-12
NCT00161304
2004-11
NCT00260143
2006-06
NCT00399165
2007-05
NCT01017458
2008-08
NCT00493987
2010-03
4 further recorded trials
NCT01601327
2012-03
NCT01962454
2015-03-20
NCT02203656
2017-12
NCT02990533
2020-11-08
Q10
At the median, Testosterone enanthate's trials enrolled 56.5 people — anything larger?
Median enrolment
56.5
Largest enrolment
222
Registered trials counted
38
Q11
What do 1361 spontaneous reports say about Testosterone enanthate — and not say?
These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.
Testosterone enanthate appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 1361 reaction mentions were counted: blood testosterone decreased 328; deep vein thrombosis 180; pulmonary embolism 161; drug abuse 150. open-targets-adr · CHEMBL1200335 · 2026-06-24
Show the evidence
blood testosterone decreased
328
deep vein thrombosis
180
pulmonary embolism
161
drug abuse
150
blood testosterone increased
135
polycythaemia
99
4 more recorded rows
myocardial infarction
98
osteonecrosis
75
acute myocardial infarction
68
prostate cancer
67
recorded 2026-06-24 · last checked 2026-09-04
Q12
Was Testosterone enanthate studied with exercise?
exercise is named in Testosterone enanthate's label sentences: "We collected functional magnetic resonance imaging (fMRI) data from 50 non-obese males before and shortly after 28 days of severe exercise-and-diet-induced energy deficit, during which testosterone (200 mg testosterone enanthate per week in sesame oil) or placebo (sesame seed oil only) was…" openfda-label+europepmc · 2022-12-05
1 recorded statement; exercise
Show the evidence
exercise
We collected functional magnetic resonance imaging (fMRI) data from 50 non-obese males before and shortly after 28 days of severe exercise-and-diet-induced energy deficit, during which testosterone (200 mg testosterone enanthate per week in sesame oil) or placebo (sesame seed oil only) was administered.
recorded 2022-12-05 · last checked 2026-09-04
Where it is registeredIdentifiers, relations and other names
ClinicalTrials.gov — US Government work · Europe PMC — metadata only, under the recorded legal gate · Open Targets 26.06 — CC0 · derived from this page's own recorded fields; no external licence · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work
✗ required summary fields resolved: 5 required field(s) not terminal: Why people use it, Best-supported result, Most important common problem, Biggest unanswered question, Human evidence
✓ public claims reviewed: 0 reviewed claim(s); drafts are never rendered
✓ source coverage passed: 8 source rows
✓ no critical contamination: no quarantine open
✓ canonical metadata passed: slug and display name present
✓ no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.